RGNX
That gene-therapy glow got a lot dimmer
REGENXBIO was selling the dream: RGX-111 could be a potential treatment for MPS I, and maybe even a path to FDA approval down the road. Then the FDA stepped in on January 28, 2026 and put the therapy on clinical hold after a preliminary review of a serious adverse event. Ouch.
Now comes the legal side quest
The new wrinkle is a securities fraud class action in federal court in Maryland. The claim, in plain English, is that REGENXBIO allegedly painted too rosy a picture of RGX-111’s prospects while the trial was wobbling behind the scenes.
For biotech investors, this is the classic double-whammy: scientific risk plus courtroom risk. One can wreck the story. Two can turn it into a full-blown cautionary tale.
Why you should care
The stock already took a 17.8% one-day hit after the FDA hold news, which tells you the market wasn’t exactly feeling zen. A class action can add more overhang, more headline risk, and more reasons for investors to keep one hand on the exit ramp.
Big picture: when a pipeline story turns into a legal story, the multiple usually doesn’t thank you for it.